Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors

Clinical Colorectal Cancer

Volumn 9, Issue 1, 2010, Pages 40-47

  Auman, James Todd ^a   McLeod, Howard L ^a  

^a University of North Carolina   (United States)

Author keywords

5 Fluorouracil; Clustering; FOLFIRI; Gene expression profiling; Microarray; Oxaliplatin

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; INFORMATION PROCESSING; LIVER CANCER; LUNG CANCER; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHARMACOGENOMICS; PRINCIPAL COMPONENT ANALYSIS; SERUM RESPONSIVE ELEMENT;

EID: 77149157822     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.005     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
2. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for nodepositive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002; 236:416-421, discussion 21.
3. Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007; 25:773-780
4. Graudens E, Boulanger V, Mollard C, et al. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006; 7:R19.
5. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-1571
6. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526-3535
7. Barrier A, Boelle P-Y, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685-4691
8. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24:227-235
9. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24:236-244 (Pubitemid 30132190)
10. Ring BZ, Chang S, Ring LW, et al. Gene expression patterns within cell lines are predictive of chemosensitivity. BMC Genomics 2008; 9:74.
11. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6:813-823
12. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12:1294-1300
13. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001; 98:10787-10792
14. Wang W, Cassidy J, O'Brien V, et al. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 2004; 64:8167-8176
15. Boyer J, Allen WL, McLean EG, et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 2006; 66:2765-2777
16. Shimizu D, Ishikawa T, Ichikawa Y, et al. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 2005; 27:371-376
17. Schmidt WM, Kalipciyan M, Dornstauder E, et al. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 2004; 112:200-212
18. de Angelis PM, Fjell B, Kravik KL, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004; 24:1279-1288
19. Martinez-Cardús A, Martinez-Balibrea E, Bandrés E, et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 2009; 8:194-202.
20. Allen WL, Coyle VM, Jithesh PV, et al. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res 2008; 14:6647-6655
21. Györffy B, Surowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006; 118:1699-1712
22. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63:8791-8812
23. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91:931-946
24. Meynard D, Le Morvan V, Bonnet J, et al. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity. Oncol Rep 2007; 17:1213-1221
25. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 2007; 35:D760-5.
26. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-210
27. Wu Z, Irizarry RA, Gentleman R, et al. A Model Based Background Adjustment for Oligonucleotide Expression Arrays. Technical Report, in Department of Statistics Working Papers. 2004, Johns Hopkins University: Baltimore, MD, 2003.
28. Dennis G, Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4:3.
29. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
30. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2:e7.
31. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-357
32. Kim I-J, Kang HC, Jang S-G, et al. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. Carcinogenesis 2006; 27:392-404.
33. Liu X, Yu X, Zack D, et al. TiGER: A database for tissue-specific gene expression and regulation. BMC Bioinformatics 2008; 9:271.
34. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 1990; 111:567-580
35. Oda Y, Herrmann J, Gitt MA, et al. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. J Biol Chem 1993; 268:5929-5939
36. Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 2000; 915:136-143
37. Williams SJ, Wreschner DH, Tran M, et al. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J Biol Chem 2001; 276:18327-18336
38. Smith MJ, Culhane AC, Donovan M, et al. Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification. Br J Cancer 2009; 100:1452-1464
39. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004; 363:1283-1285 (Pubitemid 38496491)
40. Ooyama A, Takechi T, Toda E, et al. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci 2006; 97:510-522
41. Arango D, Wilson AJ, Shi Q, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91:1931-1946
42. Barrier A, Boelle P-Y, Lemoine A, et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 2005; 48:2238-2248
43. Barrier A, Roser F, Boelle PY, et al. Prognosis of stage II colon cancer by nonneoplastic mucosa gene expression profiling. Oncogene 2007; 26:2642-2648
44. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-130